Tuberculous Meningitis in Children and Adolescents (Age 19 or Younger) Without HIV Co-infection
This protocol covers the management of tuberculous meningitis in patients aged 19 years or younger in whom HIV co-infection is absent — a population for which current guidelines identify distinct evidence-based approaches.
Clinical Scenario
Age 19 years or younger; tuberculous meningitis; HIV co-infection confirmed absent. This age group is recognised in current international guidance as having specific management considerations — including regimen duration options that differ from the standard approach used in older patients.
Treatment Approach
When an inflammatory complication such as a paradoxical reaction arises during treatment, the protocol specifies corticosteroid-based management — including particular escalation and tapering strategies. The complete regimen, sequencing, and full decision algorithm are available in the structured protocol below.
References
DOI: 10.1016/S1473-3099(25)00364-0
- For children and adolescents aged 19 years or younger with drug-susceptible tuberculous meningitis, WHO recently recommended that a 6-month regimen (isoniazid 15–20 mg/kg per day, rifampicin 22·5–30 mg/kg per day, and pyrazinamide 35–45 mg/kg per day, and the substitution of ethambutol with ethionamide at 17·5–22·5 mg/kg per day) can be used instead of the 12-month standard regimen.
- Is there HIV co-infection?
- Increase or prolong corticosteroids; in refractory cases consider other immunomodulating agents (eg, anti-TNF, thalidomide, or anakinra)
- Expert opinion recommends using high-dose corticosteroids initially (eg, dexamethasone at 0·4 mg/kg per day), tapering slowly according to symptom resolution.
View source ↗